Ripertamab
Based on 1 Customer Validation
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- CAS No.: 2249927-04-4
- Molecular Weight:144.56 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD20/MS4A1
In Vitro
Ripertamab specifically binds to the CD20 antigen on the surface of B cells, and effectively eliminates CD20-positive B cells through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and direct growth inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Ripertamab. The EC50 for this effect is 4.506 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ripertamab (HY-P99952). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2249927-04-4
-
Appearance Liquid
-
Molecular Weight 144.56 kDa
-
Color Colorless to light yellow
-
SMILES
[Ripertamab]
-
Synonyms
SCT400
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Crescioli S, et al. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538. [Content Brief]
[2]. Wang X, et al. Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study. Front Immunol. 2025;16:1540694. Published 2025 Mar 26. [Content Brief]
[3]. Li X, et al. The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study. Sci Rep. 2025;15(1):20567. Published 2025 Jul 1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ripertamab
- 2249927-04-4
- SCT400
- SCT 400
- SCT-400
- CD20
- CD20 antigen
- B-cell non-Hodgkin lymphoma
- regulatory T-cell
- antibody-dependent cell-mediated cytotoxicity
- complement-dependent cytotoxicity
- idiopathic membranous nephropathy
- CD20-positive B cells
- transmembrane CD20
- B-cell surfaces
- primary membranous nephropathy
- Inhibitor
- inhibitor
- inhibit